Latest news
Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS) - globenewswire.comglobenewswire.com · Thu, 06 Aug 2026 11:00:00 GMTHut 8: Market Misreads Q2, Beacon Point Full Commercialization Is The Signal (NASDAQ:HUT) - Seeking AlphaSeeking Alpha · Wed, 05 Aug 2026 09:56:21 GMTOak Hill Bio Announces Dosing of First Participant in - globenewswire.comglobenewswire.com · Tue, 28 Jul 2026 12:00:00 GMT